SGLT2 inhibition — a novel strategy for diabetes treatment
Authors:
- Edward C. ChaoECEdward C. Chao
- Robert R. HenryRHRobert R. Henry
Top Cited Papers
- 28 May 2010
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 9 (7) , 551-559
Abstract
Inhibiting sodium-glucose co-transporters (SGLTs), which have a key role in the reabsorption of glucose in the kidney, has been proposed as a novel therapeutic strategy for diabetes. Genetic mutations in the kidney-specific SGLT2 isoform that result in benign renal glycosuria, as well as preclinical and clinical studies with SGLT2 inhibitors in type 2 diabetes, support the potential of this approach. These investigations indicate that elevating renal glucose excretion by suppressing SGLT2 can reduce plasma glucose levels, as well as decrease weight. Although data from ongoing Phase III trials of these agents are needed to more fully assess safety, results suggest that the beneficial effects of SGLT2 inhibition might be achieved without exerting significant side effects--an advantage over many current diabetes medications. This article discusses the role of SGLT2 in glucose homeostasis and the evidence available so far on the therapeutic potential of blocking these transporters in the treatment of diabetes.Keywords
This publication has 33 references indexed in Scilit:
- Multiple‐Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double‐Blind StudyThe Journal of Clinical Pharmacology, 2010
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin SensitizersDiabetes Care, 2009
- Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implicationsKidney International, 2009
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 DiabetesDiabetes Care, 2008
- Islet cell failure in type 2 diabetesJournal of Clinical Investigation, 2006
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuriaHuman Genetics, 2003
- Glucotoxicity and β-Cell Failure in Type 2 Diabetes MellitusJournal of Pediatric Endocrinology and Metabolism, 2003
- Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)Human Genetics, 2002
- EFFECT OF DIABETES AND INSULIN ON THE MAXIMUM CAPACITY OF THE RENAL TUBULES TO REABSORB GLUCOSE 1Journal of Clinical Investigation, 1951